Hurley Capital’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$227 Hold
6
– – ﹤0.01% 628
2026
Q2
$288 Hold
6
– – ﹤0.01% 636
2026
Q1
$221 Buy
+6
New +$284 ﹤0.01% 639
2025
Q3
– Sell
-160
Closed -$11K – 698
2025
Q2
$11K Hold
160
– – 0.01% 299
2025
Q1
$11.1K Hold
160
– – 0.01% 312
2024
Q4
$14K Hold
160
– – 0.01% 254

Other funds holding NVO

Hurley Capital's NVO Position: Q3 2026 in Review

Hurley Capital held its Novo Nordisk (NVO) position steady in Q3 2026 at 6 shares worth $227. The position accounts for ﹤0.01% of the portfolio, ranked #628.

Hurley Capital first reported a position in NVO in Q4 2024 and has held it in 6 quarters since. The position peaked at $14K in Q4 2024. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Hurley Capital held 6 shares of Novo Nordisk worth $227 as of Q3 2026.
  • Hurley Capital left its Novo Nordisk share count unchanged in Q3 2026.
  • Novo Nordisk made up ﹤0.01% of Hurley Capital's portfolio in Q3 2026, its #628 holding.
  • Hurley Capital first reported a position in Novo Nordisk in Q4 2024 and has held it in 6 quarters since.
  • Hurley Capital's Novo Nordisk position peaked at $14K in Q4 2024.
  • 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Hurley Capital's 13F filing for Q3 2026, filed 5 Nov 2026.